N-acetylcysteine alleviates the meconium-induced acute lung injury

D Mokra1, A Drgova, M Petras

  • 1Department of Physiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 4 Mala Hora St., SK-03601, Martin, Slovakia, mokra@jfmed.uniba.sk.

Insights

N-acetylcysteine significantly improved lung function in a meconium aspiration syndrome (MAS) animal model. This antioxidant reduced inflammation, edema, and airway hyperreactivity, offering a potential therapeutic approach for MAS.

Area of Science:

  • Neonatal Medicine
  • Pulmonology
  • Pharmacology

Background:

  • Meconium aspiration syndrome (MAS) in newborns leads to lung inflammation and injury.
  • Oxidative stress and inflammation are key pathological features of MAS.

Purpose of the Study:

  • To investigate the therapeutic effects of N-acetylcysteine (NAC) on respiratory and inflammatory parameters in a rabbit model of MAS.
  • To evaluate NAC's impact on oxidative stress and airway reactivity.

Main Methods:

  • MAS was induced by intratracheal meconium instillation in oxygen-ventilated rabbits.
  • Animals received intravenous N-acetylcysteine or were untreated.
  • Respiratory parameters, leukocyte counts, lung edema, peroxidation (TBARS), and airway reactivity were assessed.

Main Results:

  • Meconium instillation caused polymorphonuclear-derived inflammation and oxidative stress.
  • N-acetylcysteine administration improved oxygenation and reduced lung edema.
  • NAC decreased polymorphonuclear cells in bronchoalveolar lavage fluid and diminished peroxidation and airway hyperreactivity.

Conclusions:

  • N-acetylcysteine demonstrated significant therapeutic benefits in an animal model of MAS.
  • NAC effectively mitigated inflammation, oxidative stress, and lung injury associated with meconium aspiration.
  • These findings suggest N-acetylcysteine as a potential treatment for MAS.

Related Concept Videos

Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
725
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.9K
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.4K
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
19